Literature DB >> 20888325

DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.

Grant D Stewart1, Jyoti Nanda, Elad Katz, Karen J Bowman, Jill G Christie, D J Gordon Brown, Duncan B McLaren, Antony C P Riddick, James A Ross, George D D Jones, Fouad K Habib.   

Abstract

Prostate cancer cells can exist in a hypoxic microenvironment, causing radioresistance. Nitric oxide (NO) is a radiosensitiser of mammalian cells. NO-NSAIDs are a potential means of delivering NO to prostate cancer cells. This study aimed to determine the effect and mechanism of action of NO-sulindac and radiation, on prostate cancer cells and stroma, under normoxia (21% oxygen) and chronic hypoxia (0.2% oxygen). Using clonogenic assays, at a surviving fraction of 10% the sensitisation enhancement ratios of radiation plus NO-sulindac over radiation alone on PC-3 cells were 1.22 and 1.42 under normoxia and hypoxia, respectively. 3D culture of PC-3 cells revealed significantly reduced sphere diameter in irradiated spheres treated with NO-sulindac. Neither NO-sulindac nor sulindac radiosensitised prostate stromal cells under normoxia or hypoxia. HIF-1α protein levels were reduced by NO-sulindac exposure and radiation at 21 and 0.2% oxygen. Alkaline Comet assay analysis suggested an increased rate of single strand DNA breaks and slower repair of these lesions in PC-3 cells treated with NO-sulindac prior to irradiation. There was a higher level of γ-H2AX production and hence double strand DNA breaks following irradiation of NO-sulindac treated PC-3 cells. At all radiation doses and oxygen levels tested, treatment of 2D and 3D cultures of PC-3 cells with NO-sulindac prior to irradiation radiosensitised PC-3, with minimal effect on stromal cells. Hypoxia response inhibition and increased DNA double strand breaks are potential mechanisms of action. Neoadjuvent and concurrent use of NO-NSAIDs have the potential to improve radiotherapy treatment of prostate cancer under normoxia and hypoxia. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20888325     DOI: 10.1016/j.bcp.2010.09.022

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  Multi-arm polymeric nanocarrier as a nitric oxide delivery platform for chemotherapy of head and neck squamous cell carcinoma.

Authors:  Shaofeng Duan; Shuang Cai; Qiuhong Yang; M Laird Forrest
Journal:  Biomaterials       Date:  2012-01-26       Impact factor: 12.479

2.  Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair.

Authors:  Jui-Ling Hsu; Pui-Kei Leong; Yunn-Fang Ho; Lih-Ching Hsu; Pin-Hsuan Lu; Ching-Shih Chen; Jih-Hwa Guh
Journal:  Cancer Lett       Date:  2012-01-17       Impact factor: 8.679

Review 3.  Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences.

Authors:  C Bayer; P Vaupel
Journal:  Strahlenther Onkol       Date:  2012-03-29       Impact factor: 3.621

4.  Synergistic Therapy Using Doxorubicin-Loading and Nitric Oxide-Generating Hollow Prussian Blue Nanoparticles with Photoacoustic Imaging Potential Against Breast Cancer.

Authors:  Jijun Fu; Qianni Wu; Yuanye Dang; Xueping Lei; Guining Feng; Mingyue Chen; Xi-Yong Yu
Journal:  Int J Nanomedicine       Date:  2021-08-31

Review 5.  The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.

Authors:  Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2018-02-14       Impact factor: 5.858

6.  Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide.

Authors:  Yuval Samuni; David A Wink; Murali C Krishna; James B Mitchell; Sara Goldstein
Journal:  Free Radic Biol Med       Date:  2014-05-28       Impact factor: 7.376

Review 7.  NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.

Authors:  Jan Scicinski; Bryan Oronsky; Shoucheng Ning; Susan Knox; Donna Peehl; Michelle M Kim; Peter Langecker; Gary Fanger
Journal:  Redox Biol       Date:  2015-07-02       Impact factor: 11.799

8.  Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.

Authors:  Marte Jonsson; Harald Bull Ragnum; Cathinka Halle Julin; Andree Yeramian; Trevor Clancy; Kari-Anne Myrum Frikstad; Therese Seierstad; Trond Stokke; Xavier Matias-Guiu; Anne Hansen Ree; Kjersti Flatmark; Heidi Lyng
Journal:  Br J Cancer       Date:  2016-09-06       Impact factor: 7.640

9.  Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer.

Authors:  Becky A S Bibby; Niluja Thiruthaneeswaran; Lingjian Yang; Ronnie R Pereira; Elisabet More; Darragh G McArt; Paul O'Reilly; Robert G Bristow; Kaye J Williams; Ananya Choudhury; Catharine M L West
Journal:  BMC Urol       Date:  2021-07-01       Impact factor: 2.264

Review 10.  Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities.

Authors:  Venessa T Chin; Adnan M Nagrial; Angela Chou; Andrew V Biankin; Anthony J Gill; Paul Timpson; Marina Pajic
Journal:  Expert Rev Mol Med       Date:  2015-10-28       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.